Ligand Pharmaceuticals LGND announced that
data from preclinical studies on its granulocyte colony stimulating
factor (G-CSF) receptor agonist program were featured in a poster
presentation today at the 55th Annual Meeting of the American
Society of Hematology (ASH) in New Orleans.
In preclinical studies, Ligand evaluated the ability of LGD-7455 to
stimulate neutrophil (white blood cell) counts in cynomolgus monkeys and
investigated the role that metal ions play in the activity of LGD-7455
on the G-CSF receptor (G-CSFR). Additionally, the effects and mechanisms
of LGD-7455 on tumor cell growth were examined.
The key findings include:
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in